Alkermes Plc (ALKS) Expected to Post Quarterly Sales of $254.39 Million
Wall Street analysts expect Alkermes Plc (NASDAQ:ALKS) to report $254.39 million in sales for the current quarter, Zacks reports. Five analysts have provided estimates for Alkermes’ earnings. The lowest sales estimate is $244.50 million and the highest is $261.40 million. Alkermes reported sales of $304.64 million during the same quarter last year, which would suggest a negative year-over-year growth rate of 16.5%. The firm is scheduled to issue its next quarterly earnings results on Thursday, July 25th.
According to Zacks, analysts expect that Alkermes will report full year sales of $1.17 billion for the current financial year, with estimates ranging from $1.14 billion to $1.18 billion. For the next year, analysts anticipate that the business will post sales of $1.11 billion, with estimates ranging from $1.04 billion to $1.19 billion. Zacks’ sales calculations are an average based on a survey of analysts that follow Alkermes.
Alkermes (NASDAQ:ALKS) last posted its quarterly earnings results on Thursday, April 25th. The company reported ($0.17) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.38) by $0.21. Alkermes had a negative net margin of 15.86% and a negative return on equity of 2.08%. The business had revenue of $223.10 million during the quarter, compared to analyst estimates of $218.84 million. During the same period in the previous year, the business posted ($0.09) EPS. The company’s quarterly revenue was down .9% on a year-over-year basis.
ALKS stock traded down $0.08 during midday trading on Monday, reaching $23.95. The company had a trading volume of 712,199 shares, compared to its average volume of 989,645. The company has a quick ratio of 2.65, a current ratio of 2.94 and a debt-to-equity ratio of 0.25. Alkermes has a fifty-two week low of $23.36 and a fifty-two week high of $51.70. The company has a market cap of $3.76 billion, a P/E ratio of -342.14 and a beta of 1.72.
In other news, Director Richard F. Pops sold 110,000 shares of the business’s stock in a transaction that occurred on Thursday, May 23rd. The stock was sold at an average price of $24.88, for a total transaction of $2,736,800.00. Following the completion of the transaction, the director now directly owns 776,433 shares in the company, valued at $19,317,653.04. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Paul J. Mitchell sold 1,000 shares of the business’s stock in a transaction that occurred on Monday, April 1st. The stock was sold at an average price of $36.64, for a total value of $36,640.00. Following the transaction, the director now owns 8,000 shares of the company’s stock, valued at $293,120. The disclosure for this sale can be found here. Insiders have sold a total of 352,373 shares of company stock valued at $10,123,550 over the last three months. 4.71% of the stock is currently owned by company insiders.
Several hedge funds and other institutional investors have recently modified their holdings of the company. Meeder Asset Management Inc. lifted its stake in shares of Alkermes by 155.3% in the 4th quarter. Meeder Asset Management Inc. now owns 1,810 shares of the company’s stock worth $53,000 after acquiring an additional 1,101 shares during the period. Pendal Group Ltd acquired a new stake in shares of Alkermes in the 1st quarter worth approximately $82,000. Globeflex Capital L P acquired a new stake in shares of Alkermes in the 1st quarter worth approximately $148,000. Quantamental Technologies LLC acquired a new stake in shares of Alkermes in the 4th quarter worth approximately $140,000. Finally, LPL Financial LLC acquired a new stake in shares of Alkermes in the 3rd quarter worth approximately $212,000. Institutional investors and hedge funds own 96.37% of the company’s stock.
Alkermes Company Profile
Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. The company's marketed products include ARISTADA (aripiprazole lauroxil), an extended-release intramuscular injectable suspension for the treatment of schizophrenia; VIVITROL (naltrexone for extended-release injectable suspension) for the treatment of alcohol and opioid dependence; RISPERDAL CONSTA for the treatment of schizophrenia and bipolar I disorder; INVEGA SUSTENNA for the treatment of schizophrenia and schizoaffective disorder; XEPLION, INVEGA TRINZA, and TREVICTA for treating schizophrenia; and AMPYRA (dalfampridine)/FAMPYRA (fampridine) to enhance walking in adults with multiple sclerosis (MS) who have walking disability.
Featured Story: What is systematic risk?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Alkermes Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alkermes and related companies with MarketBeat.com's FREE daily email newsletter.